IO Biotech, Inc.(IOBT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IOBT IO Biotech, Inc.

Pre-Market Trading 03-17 04:37:24 EDT

0.8788

-0.0112

-1.26%

High0.9220	Low0.8640	Vol42.41K
Open0.8900	D1 Closing0.8900	Amplitude6.52%
Mkt Cap57.90M	Tradable Cap27.61M	Total Shares65.88M
T/O37.57K	T/O Rate0.14%	Tradable Shares31.42M
P/B0.80	ROE-78.50%	EPS-1.37
52wk High1.85	52wk Low0.6600	P/E-0.64
Dividend0.00	Div.Yield0.00	ROA-45.91%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"IOBT","market":"US","secType":"STK","nameCN":"IO Biotech, Inc.","latestPrice":0.8788,"timestamp":1741982400000,"preClose":0.89,"halted":0,"volume":42414,"delay":0,"floatShares":31415821,"shares":65880914,"eps":-1.369985,"marketStatus":"Pre-Market Trading","change":-0.0112,"latestTime":"03-17 04:37:21 EDT","open":0.89,"high":0.922,"low":0.864,"amount":37565.730309,"amplitude":0.065169,"askPrice":1.08,"askSize":100,"bidPrice":0.7499,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.369985,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742218200000},"marketStatusCode":1,"adr":0,"listingDate":1636084800000,"exchange":"NASDAQ","adjPreClose":0.8788,"postHourTrading":{"tag":"盘后","latestPrice":0.905,"preClose":0.8788,"latestTime":"18:48 EDT","volume":602,"amount":542.3188,"timestamp":1741992521005},"volumeRatio":0.6349534254566471},"requestUrl":"/m/hq/s/IOBT","defaultTab":"news","newsList":[{"id":"2517653122","title":"Promising Clinical Developments and Delayed Data Boost IO Biotech’s Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517653122","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517653122?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 13:45","pubTimestamp":1741326344,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), with a price target of $12.00. Emily Bodnar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-delayed-data-boost-io-biotechs-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-delayed-data-boost-io-biotechs-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IOBT"],"gpt_icon":0},{"id":"2517512265","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2517512265","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517512265?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 13:40","pubTimestamp":1741326013,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IO Biotech (IOBT – Research Report) and Elevation On...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-667?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-667?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4137","HCSG","IOBT"],"gpt_icon":0},{"id":"2517618915","title":"IO Biotech Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517618915","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517618915?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 20:05","pubTimestamp":1741176300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IOBT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2025 07:05 ET (12:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOBT"],"gpt_icon":0},{"id":"2517982403","title":"IO Biotech Advances Phase 3 Trial and Secures Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2517982403","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517982403?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 06:16","pubTimestamp":1741126589,"startTime":"0","endTime":"0","summary":"An update from IO Biotech ( ($IOBT) ) is now available. On March 4, 2025, IO Biotech announced significant progress in its clinical trials and fina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/io-biotech-advances-phase-3-trial-and-secures-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/io-biotech-advances-phase-3-trial-and-secures-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IOBT","BK4139"],"gpt_icon":0},{"id":"2517407989","title":"IO Biotech Reports 2024 Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2517407989","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517407989?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 05:17","pubTimestamp":1741123020,"startTime":"0","endTime":"0","summary":"Preparations for submission of a Biologics License Application  for Cylembio  to FDA by year end 2025 remain on track.The trial completed enrollment in December 2023 ahead of plan with 407 patients. The primary endpoint of the pivotal Phase 3 trial is progression free survival ; the rate of PFS events has slowed and the readout of the primary endpoint is now expected in the third quarter of 2025. Dr. Zocca continued, “There is still a significant unmet medical need for new treatment options for patients suffering from advanced melanoma, metastatic head and neck cancer, and metastatic lung cancer. The full IO Biotech team is proud to be leading the next frontier of immune-oncology with the development of therapeutic cancer vaccines for these and other difficult-to-treat cancers. Our investigational therapeutic cancer vaccines are designed with a unique mechanism of action capable of targeting both immune-suppressive cells in the tumor microenvironment  and cancer cells, which have demon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/io-biotech-reports-2024-business-211700053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJJMRZ35.SGD","LU2112291526.USD","LU1917777945.USD","LU0965509283.SGD","IE00BBT3K403.USD","LU0070302665.USD","BK4588","LU1069347547.HKD","BK4139","SG9999002232.USD","LU2468319806.SGD","IE00BLSP4452.SGD","LU0006306889.USD","LU0965509010.AUD","LU1057294990.SGD","IE000M9KFDE8.USD","BK4559","LU0106261372.USD","LU1430594728.SGD","ORR","LU2461242641.AUD","BK4195","LU0861579265.USD","IE00BLSP4239.USD","SG9999002224.SGD","TME","LU1066051225.USD","LU0203345920.USD","LU0985320562.USD","PFS","SG9999013999.USD","BK4563","LU0208291251.USD","BK4534","LU1035773651.USD","IOBT","IE00BN8TJ469.HKD","LU0289739699.SGD","SG9999001176.SGD","SG9999001176.USD","LU0238689110.USD","LU0266013472.USD","SG9999001440.SGD","SG9999014542.SGD","MRK","01698","LU2023250504.SGD","IE00BYTNYN87.SGD","IE00BJT1NW94.SGD","LU2039709279.SGD"],"gpt_icon":0},{"id":"2513022759","title":"IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2513022759","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513022759?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 01:07","pubTimestamp":1740330420,"startTime":"0","endTime":"0","summary":" Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors NEW YORK, Feb.  23, 2025  (GLOBE NEWSWIRE) -- I","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/23/3030818/0/en/IO-Biotech-Announces-New-Preclinical-Data-for-Additional-Pipeline-Candidate-Presented-at-the-AACR-IO-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU0359202008.SGD","IE00B12V2V27.USD","BK4565","IOBT","BK4139","BK4531","BK4548","LU1023057109.AUD","TME","BK4563","BK4552","IE00BYTNYN87.SGD","BK4108","BK4509","01698","BK4526","LU2039709279.SGD","LU0359201612.USD","BK4571","SG9999011746.SGD","IE00BYQNZ168.SGD"],"gpt_icon":0},{"id":"2508698459","title":"IO Biotech announces publication of preclinical data on IO112","url":"https://stock-news.laohu8.com/highlight/detail?id=2508698459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508698459?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 21:27","pubTimestamp":1738675628,"startTime":"0","endTime":"0","summary":"IO Biotech (IOBT) announced the publication of results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/io-biotech-announces-publication-of-preclinical-data-on-io112?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/io-biotech-announces-publication-of-preclinical-data-on-io112?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IOBT","BK4139","BK4179","IO","BK4563"],"gpt_icon":0},{"id":"2508456058","title":"IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2508456058","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508456058?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 21:05","pubTimestamp":1738674300,"startTime":"0","endTime":"0","summary":"–Submission of Investigational New Drug Application (IND) to US FDA expected in 2025–  NEW YORK, Feb.  04, 2025  (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical compa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/04/3020277/0/en/IO-Biotech-Announces-Publication-of-Preclinical-Data-Investigating-Immune-Modulatory-Effects-of-IO112-an-Arginase-1-Targeting-Therapeutic-Cancer-Vaccine-Candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","01698","BK4563","BK4526","BK4179","BK4548","BK4509","IE00BYTNYN87.SGD","IE00B12V2V27.USD","IO","BK4535","BK4565","BK4531","IOBT","LU0359202008.SGD","LU1023057109.AUD","LU2039709279.SGD","SG9999011746.SGD","TME","IE00BYQNZ168.SGD","LU0359201612.USD","BK4552","BK4571","BK4108"],"gpt_icon":0},{"id":"2502027888","title":"IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2502027888","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502027888?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 05:24","pubTimestamp":1736457877,"startTime":"0","endTime":"0","summary":"IO Biotech  said Thursday it completed enrollment ahead of schedule in a phase 2 trial of its cancer vaccine candidate IO102-IO103 combined with Merck's  Keytruda to treat people with resectable melanoma or squamous cell carcinoma of the head and neck.Initial data is expected this year, the company said.The trial has enrolled 93 people in the US, Europe and Australia, the company added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0006306889.USD","LU1037948897.HKD","LU1116320901.HKD","SG9999014575.USD","LU2361044865.SGD","LU1917777945.USD","BK4534","IE0002141913.USD","LU0070302665.USD","LU0234572021.USD","IE0009355771.USD","IE00BBT3K403.USD","LU1066051498.USD","LU1585245621.USD","LU1989771016.USD","LU0861579265.USD","LU1989772923.USD","LU0211331839.USD","LU0965509283.SGD","LU2361045086.USD","LU1037948541.HKD","LU0106261372.USD","LU1989772840.SGD","LU0985320562.USD","LU0238689110.USD","IE00B2B36J28.USD","LU1093756325.SGD","LU1023059063.AUD","SG9999001176.USD","LU1934455277.USD","LU1974910355.USD","LU2089984988.USD","IOBT","LU0208291251.USD","LU1941712264.USD","IE00BJT1NW94.SGD","SG9999002224.SGD","LU1066051225.USD","IO","LU0122379950.USD","SG9999014559.SGD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","LU1941712348.USD","BK4179","SG9999001440.SGD","LU0965509010.AUD","MRK","LU1934455863.HKD","BK4559"],"gpt_icon":0},{"id":"2502010176","title":"IO Biotech completes enrollment in Phase 2 trial of IO102-IO103","url":"https://stock-news.laohu8.com/highlight/detail?id=2502010176","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502010176?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 22:05","pubTimestamp":1736431514,"startTime":"0","endTime":"0","summary":"IO Biotech (IOBT) announced it has completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial, IOB-032/PN-E40. The trial is studying IO1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/io-biotech-completes-enrollment-in-phase-2-trial-of-io102-io103?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/io-biotech-completes-enrollment-in-phase-2-trial-of-io102-io103?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IOBT","BK4563","IO","BK4179"],"gpt_icon":0},{"id":"2502459011","title":"IO Biotech Inc - Initial Data From Phase 2 Trial Expected in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502459011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502459011?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 21:05","pubTimestamp":1736427900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nTUACGHDGV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IOBT"],"gpt_icon":0},{"id":"2502119600","title":"IO Biotech Completes Enrollment in Phase 2 Trial of Its Investigational, off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients With Resectable Melanoma or Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2502119600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502119600?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 21:05","pubTimestamp":1736427900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nTUACGHDGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IOBT"],"gpt_icon":0},{"id":"2502110280","title":"IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2502110280","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502110280?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 21:05","pubTimestamp":1736427900,"startTime":"0","endTime":"0","summary":"-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan.  09, 2025  (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company dev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3007033/0/en/IO-Biotech-Completes-Enrollment-in-Phase-2-Trial-of-its-Investigational-Off-the-shelf-Therapeutic-Cancer-Vaccine-IO102-IO103-as-Neoadjuvant-Adjuvant-Treatment-for-Patients-with-Res.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU1023057109.AUD","LU2106854487.HKD","BK4108","SGXZ57979304.SGD","LU1093756325.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4166","LU0006306889.USD","LU1989771016.USD","SG9999015358.SGD","IE00BYQNZ168.SGD","BK4516","LU1430594728.SGD","LU0985320562.USD","LU2023250843.SGD","IE00BN8TJ469.HKD","BK4531","BK4552","LU1917777945.USD","LU0106831901.USD","LU1983299246.USD","LU1585245621.USD","LU0265550359.USD","IE00BLSP4452.SGD","LU2360107671.USD","TME","IE00BBT3K403.USD","BK4548","LU2361045086.USD","BK4588","BK4559","LU1571399168.USD","LU0203345920.USD","MRK","IE00BLSP4239.USD","IOBT","LU2361044949.HKD","DFS","LU1699723380.USD","LU1791807156.HKD","LU1934455863.HKD","LU0359202008.SGD","IE00B1BXHZ80.USD","LU0965509101.SGD","01698","LU1941712348.USD","BK4533","IO"],"gpt_icon":0},{"id":"2494358136","title":"BRIEF-IO Biotech Receives Nasdaq Notice For Minimum Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2494358136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494358136?lang=en_us&edition=full_marsco","pubTime":"2024-12-28 05:18","pubTimestamp":1735334285,"startTime":"0","endTime":"0","summary":"BRIEF-IO Biotech Receives Nasdaq Notice For Minimum Bid Price Non-ComplianceDec 27 (Reuters) - IO Biotech Inc IOBT.O:IO BIOTECH INC - RECEIVES NASDAQ NOTICE FOR MINIMUM BID PRICE NON-COMPLIANCEFurther company coverage: IOBT.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nFWN3NS038:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOBT","BK4139"],"gpt_icon":0},{"id":"2494358187","title":"IO Biotech Inc - Receives Nasdaq Notice for Minimum Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2494358187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494358187?lang=en_us&edition=full_marsco","pubTime":"2024-12-28 05:17","pubTimestamp":1735334239,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nFWN3NS038:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IOBT"],"gpt_icon":0},{"id":"2492497674","title":"BRIEF-Io Biotech Secures Up To €57.5 Million In Debt Financing From The European Investment Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2492497674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492497674?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 22:22","pubTimestamp":1734704530,"startTime":"0","endTime":"0","summary":"BRIEF-Io Biotech Secures Up To 57.5 Million In Debt Financing From The European Investment BankDec 20 (Reuters) - IO Biotech Inc IOBT.O:IO BIOTECH SECURES UP TO 57.5 MILLION IN DEBT FINANCING FROM THE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA6HBVLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOBT","BK4139"],"gpt_icon":0},{"id":"2492443517","title":"IO Biotech secures up to EUR 57.5M in debt financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2492443517","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492443517?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 21:15","pubTimestamp":1734700545,"startTime":"0","endTime":"0","summary":"IO Biotech (IOBT) entered into a loan facility of up to EUR 57.5M from the European Investment Bank. The debt facility includes three committed tra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/io-biotech-secures-up-to-eur-57-5m-in-debt-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/io-biotech-secures-up-to-eur-57-5m-in-debt-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4179","IOBT","IO","BK4563"],"gpt_icon":0},{"id":"2492448929","title":"IO Biotech Inc: Funds Expected to Be Used to Advance IO Biotech's Immune-Modulating Therapeutic Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2492448929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492448929?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 21:05","pubTimestamp":1734699900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA6HBVLH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IOBT"],"gpt_icon":0},{"id":"2492444899","title":"IO Biotech Secures up to €57.5 Million in Debt Financing From the European Investment Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2492444899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492444899?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 21:05","pubTimestamp":1734699900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA6HBVLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IOBT","BK4139"],"gpt_icon":0},{"id":"2492132448","title":"IO Biotech Inc: Debt Facility Expected to Extend Company's Cash Runway Into Q2 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2492132448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492132448?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 21:05","pubTimestamp":1734699900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA6HBVLH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IOBT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.iobiotech.com","stockEarnings":[{"period":"1week","weight":-0.0236},{"period":"1month","weight":-0.0399},{"period":"3month","weight":0.0849},{"period":"6month","weight":0.1702},{"period":"1year","weight":-0.4831},{"period":"ytd","weight":-0.0448}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0672},{"period":"3month","weight":-0.0685},{"period":"6month","weight":0.0014},{"period":"1year","weight":0.0929},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.11102},{"month":2,"riseRate":0.25,"avgChangeRate":-0.068431},{"month":3,"riseRate":0.25,"avgChangeRate":-0.128113},{"month":4,"riseRate":0.666667,"avgChangeRate":0.076841},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.145523},{"month":6,"riseRate":0,"avgChangeRate":-0.033899},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.025428},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.010336},{"month":9,"riseRate":0,"avgChangeRate":-0.239144},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.09996},{"month":11,"riseRate":0.666667,"avgChangeRate":0.087089},{"month":12,"riseRate":0.5,"avgChangeRate":0.029221}],"exchange":"NASDAQ","name":"IO Biotech, Inc.","nameEN":"IO Biotech, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IO Biotech, Inc.(IOBT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IO Biotech, Inc.(IOBT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IO Biotech, Inc.,IOBT,IO Biotech, Inc.股票,IO Biotech, Inc.股票老虎,IO Biotech, Inc.股票老虎国际,IO Biotech, Inc.行情,IO Biotech, Inc.股票行情,IO Biotech, Inc.股价,IO Biotech, Inc.股市,IO Biotech, Inc.股票价格,IO Biotech, Inc.股票交易,IO Biotech, Inc.股票购买,IO Biotech, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IO Biotech, Inc.(IOBT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IO Biotech, Inc.(IOBT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction